GlassScriptPhysician profile
Maria R Hellkamp
NPI 1235297334
$1,512.63
in general payments reported to CMS, 2019-2025
15 companies · $231 in 2025
The $231 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $279 · 2022: $189 · 2023: $220 · 2024: $593 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $724 · Education: $170 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $724.35 |
| Education | $170.00 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $346.25 | 2022-2025 | |
| Janssen Biotech, INC. | $311.34 | 2021-2025 | Rybrevant, Carvykti, Tecvayli |
| Legend Biotech USA INC. | $139.65 | 2024 | Carvykti |
| Amgen INC. | $139.30 | 2021 | |
| Incyte Corporation | $134.81 | 2022-2024 | Jakafi |
| Sobi, INC | $75.57 | 2022-2024 | |
| Astellas Pharma US INC | $71.00 | 2023 | |
| Adaptive Biotechnologies Corporation | $70.50 | 2022-2024 | Clonoseq |
| Alexion Pharmaceuticals, INC. | $62.61 | 2025 | Ultomiris |
| Daiichi Sankyo INC. | $61.17 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $25.23 | 2024 | |
| Puma Biotechnology, INC. | $20.80 | 2021 | |
| Seagen INC. | $19.89 | 2021 | |
| Genentech USA, INC. | $18.62 | 2023 | Columvi, Lunsumio |
| Merck Sharp & Dohme LLC | $15.89 | 2024 | Prevymis, Dificid, Zerbaxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Hellkamp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.